Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

July 10, 2018, CU Anschutz Medical Campus
Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Virginia Borges, M.D., MMSc, and colleagues report promising phase 1b results for tucatinib and T-DM1 against HER2+ breast cancer. Credit: University of Colorado Cancer Center

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.

"At University of Colorado Cancer Center, we've worked with this drug since it was discovered by ARRAY BioPharma in Boulder. First it was ARRAY-380, then ONT-380 and now it's called tucatinib. Since then, our institution has taken a lead effort in bringing it into trials and now into places where we are seeing it provide real benefit for women," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at CU Cancer Center.

About 20 percent of breast cancers are considered HER2-positive, meaning that these overexpress "receptors" that bind human epidermal growth factor 2 (HER2). When HER2 receptors on cancer cells trap HER2, it signals the uncontrolled reproduction of these cells. However, the reverse is also true: When HER2+ are unable to bind HER2, they die.

Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 "tyrosine kinase—a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. Importantly, the fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against of the disease. HER2+ breast cancer is more likely to affect younger women and also more likely than other cancers to metastasize specifically to the brain.

"One of the best things about this drug is that it combines well with nearly everything. It is so well tolerated that when you test tucatinib in combination with other drugs, it feels like you're just giving the other drug. It's a pill. It works. And it hardly causes side effects. It's really a doctor's dream," Borges says.

Accordingly, tucatinib is being evaluated in a number of other trials and with additional partners, for example another trial offered at CU Cancer Center and elsewhere exploring the use of the drug as a component of a combination against so called triple-positive (those cancers expressing estrogen, progesterone and HER2 receptors). Borges hopes that the effectiveness of tucatinib in patients with metastatic disease who have tried previous treatments may lead to trials of the drug used earlier in the course of treatment.

In the current trial, tucatinib was combined with Ado-Trastuzumab Emtansine (T-DM1), which is one in a class of drugs known as antibody-drug conjugates. In this case, an antibody called trastuzumab that binds to HER2 is combined with a drug called emtansine that kills cells. Together, T-DM1 delivers the cell-killing drug directly to cells marked by HER2.

"It's a no-chemo regimen. Once the is approved, we hope to see this regimen come forward in the course of treatment. Ultimately, we hope it will prevent recurrences and also diminish the number of brain metastatic recurrences," Borges says.

Updated results will be presented at the San Antonio Breast Cancer Symposium in December, 2018.

Explore further: Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

More information: Virginia F. Borges et al, Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer, JAMA Oncology (2018). DOI: 10.1001/jamaoncol.2018.1812

Related Stories

Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

January 11, 2017
Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated ...

SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer

December 9, 2015
Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against ...

ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'

May 29, 2015
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically ...

New lab study reveals how breast cancer drug can accelerate cancer cell growth

May 1, 2018
The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists ...

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one ...

Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

December 6, 2017
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...

Recommended for you

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.